SpineEx has filed a registration statement with the US Securities and Exchange Commission (SEC) to raise $17m through an initial public offering.
Based in the US, SpineEx is a medical device company engaged in the development of spinal implants used to improve spinal fusion surgeries.
Second Sight Medical Products has received a $1.6m grant from the National Institutes of Health (NIH) to support the clinical development of the former’s Orion™ Cortical Visual Prosthesis (Orion).
Orion™ is a visual prosthesis device, which is used to stimulate the surface of the visual cortex to induce visual perception in people suffering from forms of blindness.
Funds will also be used to evaluate Orion’s reliability and validate its fitting process.
Based in the US, Second Sight Medical Products is a developer and manufacturer of prosthetic devices to restore functional vision in blind individuals.
AtaCor Medical has raised $8.8m through a series A financing round from Broadview Ventures and aMoon Ventures.
The funding round also included the participation of a corporate partner.
The company plans to use funds to develop extravascular substernal cardiac pacing system, a novel pacing device used to keep the heart and veins free from leads and hardware.
Based in the US, AtaCor Medical is a developer of an implantable cardiac pacing system, while Broadview Ventures is a venture capital firm based in the US. aMoon Ventures is an Israel-based investment management firm.
Aramark has signed an agreement to sell its Healthcare Technologies (HCT) business unit to Trimedx for $300m.
The transaction is part of Aramark’s strategy to focus on its core food, facilities, and uniforms businesses.
The transaction is expected to close in the last quarter of 2018, subject to customary closing conditions and other regulatory approvals.
Based in the US, Aramark is a provider of food, facilities management and uniform services to hospitals and other businesses. Trimedx is a provider of biomedical engineering and medical equipment lifecycle management services.
The deal will enable Trimedx to bolster its clinical and financial results, and enhance its device security and compliance.